Prostatectomy and radiation therapy show no survival difference for low-risk prostate cancer, but higher-risk cases require careful treatment consideration. The ProtecT trial supports active ...

Can clinico-genomic characterization reveal more aggressive prostate cancer among older patients with lower Gleason grade groups? This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I.

If you or a loved one has been diagnosed with prostate cancer, you’re not alone—and you don’t have to wait long to take the next step. Whether you’re newly diagnosed, moving from active surveillance ...

Long-term results from a phase 3 study showed that adding a focal boost to standard external beam radiotherapy (EBRT) improved 10-year biochemical disease-free survival (DFS) and reduced biochemical ...

For many men with prostate cancer, weeks of daily treatments are no longer the norm. Jonathan Tward, MD, a radiation oncologist at Huntsman Cancer Institute, explains how image guidance, real-time ...

Prostate cancer is one of the most common cancers in the world. While many prostate cancers grow slowly and remain localized, other types are aggressive and spread quickly. That's why Dr. Carlos ...